Ferring appoints Pascal Danglas and Per Falk to senior positions

Switzerland-headquartered Ferring Pharmaceuticals has appointed Pascal Danglas as executive vice president and chief medical officer, and Per Falk has been appointed executive vice president and chief scientific officer.

Michel Pettigrew, president of the executive board and chief operating officer of Ferring, said: “Ferring aims to expand its portfolio and improve patient access to our products. By focusing our efforts in R&D and patient access under these two proven leaders, Ferring is positioning itself to accelerate growth and better meet patient needs.”

Dr Danglas previously served as executive vice president of clinical and product development at Ferring, while Per Falk joins from Novo Nordisk (NOV: N) where he was senior vice president responsible for biopharma research.